In a significant case of financial fraud, 56-year-old Adrianus Johannes Kees has been sentenced to three and a half years in prison for defrauding Mayo-based biotechnology firm Ovagen of €840,000. The conviction underscores the vulnerabilities that companies, especially those in critical sectors like biotechnology, face from sophisticated fraudulent schemes.

The Fraudulent Scheme

Ovagen, a company specializing in the development of germ-free eggs for vaccine production, was in the process of raising €28 million to patent its innovative product. In 2011, Ovagen’s directors were introduced to Enerbiz, a Swiss banking company led by CEO Adrianus Johannes Kees. Kees proposed assisting Ovagen in securing the necessary funding by obtaining an irrevocable loan commitment letter, which he claimed would facilitate the acquisition of bonds to secure the funds.

Kees requested a processing fee of €840,000, assuring Ovagen that the money would be placed in an escrow account in Liechtenstein, inaccessible to anyone, and refundable within 91 days if the funding was not secured. He also claimed that Ovagen could monitor the account to verify the safety of their funds. Based on these representations, Ovagen secured a loan from Allied Irish Banks (AIB), with personal guarantees from its directors, and transferred the €840,000 to the specified account.

Discovery of the Fraud

Despite Kees’s assurances, the promised loan from HSBC never materialized. When Ovagen requested documentation, the provided papers raised suspicions. Further inquiries revealed that there was no escrow account, and the €840,000 had been swiftly dispersed within two weeks of the transfer. Investigations showed that portions of the funds were transferred to Kees’s associates, his personal bank account, and even used for personal expenses such as a ‘pool house settlement’ and a Mercedes Benz lease. By the time Ovagen sought the return of their funds, the account held a mere €3.83.

Legal Proceedings and Sentencing

Following the discovery of the fraud, a European Arrest Warrant was issued by the High Court in July 2022. Kees, residing in Valencia, Spain, was extradited and charged on September 23, 2022. Initially pleading not guilty to charges of fraud and theft, Kees changed his plea to guilty on the fifth day of the trial.

During sentencing at Dublin Circuit Criminal Court, Judge Martin Nolan emphasized the severity of the offense, noting that Kees had “deprived Ovagen of a substantial amount of money” and caused significant harm to the company and its employees. The court heard a victim impact statement from Ovagen’s CEO, Dr. Leonard Moran, who described the devastating effect of the fraud on his health and family, leading to the dismissal of staff and a profound decline in his quality of life.

Implications for the Biotechnology Sector

This case highlights the critical importance of due diligence and robust financial safeguards within the biotechnology industry. Companies engaged in high-stakes scientific development are often targets for financial fraud due to the substantial funds involved and the urgency to secure financing. Implementing stringent verification processes, consulting with financial experts, and maintaining transparency in financial transactions are essential measures to protect against such fraudulent schemes.

The sentencing of Adrianus Johannes Kees serves as a cautionary tale for businesses about the potential risks of financial fraud. It underscores the necessity for vigilance, thorough vetting of financial partners, and adherence to best practices in financial management to safeguard company assets and ensure the continuity of innovative scientific endeavors.

For more stories and insights, visit It’s On

Instagram:@itson.ie

TikTok videos and information:@itson.ie